Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

SUPPRESSION OF DRUG-METABOLIZING ENZYMES AND EFFLUX TRANSPORTERS IN THE INTESTINE OF ENDOTOXIN-TREATED RATS

J. Kalitsky-Szirtes, A. Shayeganpour, D.R. Brocks and M. Piquette-Miller
Drug Metabolism and Disposition January 2004, 32 (1) 20-27; DOI: https://doi.org/10.1124/dmd.32.1.20
J. Kalitsky-Szirtes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Shayeganpour
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D.R. Brocks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Piquette-Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Infection and inflammation impose a suppression in the expression and activity of several drug transporters and drug-metabolizing enzymes in liver. In the intestine, cytochrome P450 3A (CYP3A), P-glycoprotein (PGP/mdr1), and the multidrug resistance-associated protein 2 (MRP2) are important barriers to the absorption of many clinically important drugs; thus, the expression and activity of these proteins were examined in inflammation. Transport and metabolism were determined in jejunum segments isolated at 24 h from endotoxin-treated or control rats (n = 8) mounted in Ussing chambers. Transport and metabolism of 3H-digoxin, 5-carboxyfluorescein (5-CF), amiodarone (AM), and 7-benzyloxyquinoline (7-BQ) were measured for 90 min in the presence and absence of inhibitors. Reverse transcription-polymerase chain reaction was used to measure mRNA levels. As compared with controls, levels of mdr1a and mrp2 mRNA were significantly decreased by approximately 50% in the jejunum of LPS-treated rats. Corresponding reductions in the basolateral→apical efflux of digoxin, AM, and 5-CF were observed, resulting in significant increases in the apical→basolateral absorption of these compounds. Intestinal CYP3A mRNA levels and CYP3A-mediated metabolism of 7-BQ and AM were also decreased by approximately 50 to 70% (p < 0.05) in the LPS group. Mannitol permeability and lactate dehydrogenase release were not altered. These studies indicate that endotoxin-induced inflammation imposes a reduction in the intestinal expression and activity of PGP, mrp2, and CYP3A in rats, which elicits corresponding changes in the intestinal transport and metabolism of their substrates. Hence, infection and inflammatory diseases may impose variability in drug bioavailability through alterations in the intestinal expression and activity of drug transporters and metabolic enzymes.

Footnotes

  • ↵1 Abbreviations used are: PGP, P-glycoprotein; mdr1, multidrug resistance gene; mrp2, multidrug resistance-associated protein 2; CYP3A cytochrome P450 3A; IL, interleukin; PXR, pregnane X receptor; LPS, lipopolysaccharide; RT-PCR, reverse transcription-polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PSC-833, valspodar; OATP, organic anion transporting polypeptide; 7-BQ, 7-benzyloxyquinoline; 7-HQ, 7-hydroxyquinoline; AM, amiodarone; DEA, desethylamiodarone; HPLC, high performance liquid chromatography; 5-CF, 5-carboxyfluorescein; 5-CFDA, 5-carboxyfluorescein diacetate; A→B apical to basolateral; B→A, basolateral to apical; MK571, 3-[[3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methylsulfanyl] propionic acid; LDH, lactate dehydrogenase; O.D., optical density; AUC, area under the curve.

  • Financial support was provided by an operating grant obtained from the Canadian Institute of Health Research (CIHR). Dr. Piquette-Miller is a recipient of the Rx&D Health Research Foundation-CIHR Research Career Award.

    • Received June 16, 2003.
    • Accepted September 2, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 32 (1)
Drug Metabolism and Disposition
Vol. 32, Issue 1
1 Jan 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
SUPPRESSION OF DRUG-METABOLIZING ENZYMES AND EFFLUX TRANSPORTERS IN THE INTESTINE OF ENDOTOXIN-TREATED RATS
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

SUPPRESSION OF DRUG-METABOLIZING ENZYMES AND EFFLUX TRANSPORTERS IN THE INTESTINE OF ENDOTOXIN-TREATED RATS

J. Kalitsky-Szirtes, A. Shayeganpour, D.R. Brocks and M. Piquette-Miller
Drug Metabolism and Disposition January 1, 2004, 32 (1) 20-27; DOI: https://doi.org/10.1124/dmd.32.1.20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

SUPPRESSION OF DRUG-METABOLIZING ENZYMES AND EFFLUX TRANSPORTERS IN THE INTESTINE OF ENDOTOXIN-TREATED RATS

J. Kalitsky-Szirtes, A. Shayeganpour, D.R. Brocks and M. Piquette-Miller
Drug Metabolism and Disposition January 1, 2004, 32 (1) 20-27; DOI: https://doi.org/10.1124/dmd.32.1.20
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Series-Compartment Models of Hepatic Elimination
  • Warfarin PBPK Model with TMDD Mechanism
  • Identification of payload-containing catabolites of ADCs
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics